Skip to search formSkip to main contentSkip to account menu

CP 751871

Known as: CP-751,871, CP751,871, CP-751871 
A human monoclonal antibody directed against the insulin-like growth factor type I receptor (IGF1R) with potential antineoplastic activity. CP-751871… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

figitumumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC.
8091 Background: Signaling of Insulin like Growth Factors (IGFs) through the IGF type 1 receptor (IGF-IR) induces tumor… 
2016
2016
Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871).
3539 Background: Free IGF-1 (fIGF-1) represents the biologically active fraction of IGF-1, the main circulating ligand of the… 
2011
2011
The Efficacy of IGF-I Receptor Monoclonal Antibody against Human Gastrointestinal Carcinomas is Independent of k-ras Mutation Status
Purpose: Insulin-like growth factor (IGF)-I receptor (IGF-IR) signaling is required for carcinogenicity and proliferation of… 
2011
2011
Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC).
3525 Background: Figitumumab (F; CP-751,871) is a fully human monoclonal antibody (mAb) that inhibits IGF-IR. This phase II trial… 
2010
2010
Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies
Activation of the insulin-like growth factor (IGF) pathway, by binding of the growth factors IGF-I and IGF-II to the receptors… 
2009
2009
Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer.
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2136 Background: Aromatase inhibitors (AIs) are… 
2007
2007
Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.
  • D. Sachdev
  • Current opinion in molecular therapeutics (Print)
  • 2007
  • Corpus ID: 41192542
Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in… 
2007
2007
Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients
3587 Background: The Insulin like Growth Factor I receptor (IGF-IR), a tyrosine kinase, is widely expressed in human tissues. IGF… 
2007
2007
Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.
Background: CP-751,871, a fully human IgG2 subtype monoclonal antibody, is a potent and specific inhibitor of the insulin- like… 
2007
2007
Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors
LB-343 Background: The paradigm of using therapeutic antibodies to target growth factor receptors is now well established in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)